Trials / Conditions / High-grade Serous Ovarian Carcinoma
High-grade Serous Ovarian Carcinoma
6 registered clinical trials studyying High-grade Serous Ovarian Carcinoma — 2 currently recruiting.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Recruiting | A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors NCT07115043 | AstraZeneca | Phase 1 / Phase 2 |
| Recruiting | First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tu NCT06799065 | Accent Therapeutics | Phase 1 |
| Active Not Recruiting | Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subj NCT05827614 | Boundless Bio, Inc. | Phase 1 |
| Completed | Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002) NCT05446870 | Merck Sharp & Dohme LLC | Phase 2 |
| Unknown | Chromosomal Instability in Ovarian Cancer NCT05310357 | Lei Li | — |
| Terminated | A Study of LY3435151 in Participants With Solid Tumors NCT04099277 | Eli Lilly and Company | Phase 1 |